Advances in Microbiology
Vol.06 No.12(2016), Article ID:71273,8 pages

In Vitro Efficacy of Crataegus oxycantha L. (Hawthorn) and Its Major Components against ATCC and Clinical Strains of Ureaplasma urealyticum

Carlo Bisignano1, Pio Maria Furneri2, Giuseppina Mandalari1*

1Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Messina, Italy

2Section of Microbiology, Department of Biomedical and Biotechnological Sciences-BIOMETEC, University of Catania, Catania, Italy

Copyright © 2016 by authors and Scientific Research Publishing Inc.

This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).

Received: May 30, 2016; Accepted: October 15, 2016; Published: October 18, 2016


Crataegus oxycantha L., commonly known as hawthorn, has traditionally been used for its beneficial effect on cardiovascular health, which is related to its flavonoid content. The aim of the present study was to evaluate the antibacterial properties of a fluid extract and a hydro-ethanolic macerate from buds of Crataegus oxycantha against clinical isolates of Ureaplasma urealyticum. The major purified flavonoids present in the extracts were also tested against ATCC strains and clinical isolates. Both the fluid extract and the hydro-ethanolic macerate were active against thirty-due clinical strains of U. urealyticum, with MIC ranges between 15.6 and 250 μg/ml and 15.6 and 62.5 μg/ml, respectively. All pure organic compounds, with the exception of rutin, showed activity against the strains tested, luteolin 3,7-diglucoside being the most active compound (MICs in the range of 0.48 and 1.95 μg/ml), followed by apigenin-7-O-glucoside (MICs in the range of 0.48 and 3.9 μg/ml). The activity of the pure flavonoids was greater against the clinical isolates compared to the ATCC strains. The data presented here demonstrate that flavonoids present in Crataegus oxycantha are effective against clinical isolates of U. urealyticum and could be used in combination with antibiotics in order to combat resistance.


Crataegus oxycantha, Ureaplasma urealyticum, Flavonoids, Antimicrobial

1. Introduction

The genus Ureaplasma, considered part of the normal genital flora, is implicated in several conditions like non-gonococcal urethritis, prostatitis, urinary and gynecological diseases, infertility, and lung disease in newborns. It belongs to the family Mycoplasmataceae, class Mollicutes order Mycoplasmatales. Several classes of antibiotics have proven not to be effective against Ureaplasma species, and a recent study has reported low susceptibilities to tetracycline [1] . Therefore, discovering novel bioactive compounds from plant products could help eradicate a number of infectious diseases. The growing concern over antibiotic resistance worldwide has posed an urgent need to develop novel antibacterial compounds. There is an increased effort by food industries in finding natural compounds with potential antimicrobial properties [2] [3] .

Natural products have traditionally been regarded as a major source of important therapeutic agents, with their potential use against infectious diseases in folk medicine. Mixtures obtained by pure phytochemicals as well as plant extracts have successfully been studied for their antimicrobial properties [4] [5] .

We have previously reported the antibacterial activity of polyphenols-rich natural products, including almonds [6] [7] , pistachios [8] , Citrus plants [9] , Vitis vinifera L. [10] , Olea europaea L. [11] , Citrus bergamia essential oil [12] , and juice [13] . In particular, the identification of novel compounds with bactericidal rather than bacteriostatic effect has attracted a lot of interests in recent years.

Crataegus oxycantha L., a tree belonging to the Rosaceae family, is commonly known as hawthorn, English hawthorn, May bush and whitehorn. It has traditionally been used for its positive effect on cardiovascular health, attributed to its flavonoid content, particularly high in oligomeric proanthocyanidins [14] . Animal studies have also indicated a protective effect of Crataegus extracts on plasma lipids, including total cholesterol, triglycerides and cholesterol fractions [15] .

The flavonoid content in flowers, leafs and bud extracts from Crataegus oxycantha L. has been previously identified: the major identified compounds were luteolin, luteolin-3,7-diglucoside, apigenin, apigenin-7-O-glucoside and rutin [16] . The biological activity against arrhythmias exerted by this plant was due to the synergistic interaction amongst the several compounds with different chemical structures [16] . The study on the antibacterial activity of methanol and chloroform extracts from Crataegus oxycantha showed a bactericidal effect on pathogenic staphylococci when using flowers, with lower activity against Bacillus and Pseudomonas [17] .

The aim of the present study was to evaluate the in vitro antimicrobial properties of a fluid extract and a hydro-ethanolic macerate from Crataegus oxycantha against clinical strains of Ureaplasma urealyticum, known to play an important role in vaginal infections and sexually transmitted diseases. In addition, the antimicrobial effect of the major flavonoid compounds present in the extracts was investigated against ATCC strains and clinical isolates.

2. Materials and Methods

2.1. Crataegus oxycantha Extracts

Two different preparations from buds of Crataegus oxycantha L. were used in the study: 1 fluid extract and 1 hydro-ethanolic macerate. The extraction procedure has been previously reported [16] . Briefly, 1 ml of fluid extract (1 ml extract = 1 g of dried plant material) or 20 ml of the hydro-ethanolic macerate were extracted twice with ethyl acetate (20 ml). After evaporation of the solvent, residues were dissolved in de-ionised water (15 ml) and extracted eight times with 15 ml of ethyl acetate/acetone (2:1). The organic phases were combined and evaporated, whereas the residues were dissolved in methanol (5 ml) and analysed by HPLC. The composition of the extracts has been previously reported [16] . The major identified compounds were the following: luteolin (1.6 and 0.8 mg/ml), rutin (22.8 and 2.7 mg/ml), luteolin-3,7-diglucoside (1.8 and 0.1 mg/ml), apigenin-7-O-glucoside (0.3 and 0.2 mg/ml) in the fluid extract and the hydro-ethanolic macerate, respectively [16] .

2.2. Microbial Strains and Culture Conditions

Three American Type Culture Collection strains (Ureaplasma urealyticum serotype I ATCC 27813, Ureaplasma urealyticum serotype II ATCC 27814 and Ureaplasma urealyticum serotype VII ATCC 27819) were used in the study. Thirty-due clinical strains of U. urealyticum were isolated from cervix, urethra, vagina and placenta during caesarean section at the Institute of Obstetric and Gynaecological pathology of the University of Catania [18] . The strains are kept within the in-house collection at the University of Messina, Microbiology sector (Messina, Italy). Cultures for antimicrobial activity tests were grown in 10-B Broth (pH 6.0, Sigma, Italy) [19] . Two antibiotics, azithromycin and erythromycin, used in the antimicrobial assays were obtained from Sigma (Milan, Italy).

2.3. Antimicrobial Testing

The minimum inhibitory concentrations (MICs) of the fluid extract and the hydro- ethanolic macerate of Crataegus oxycantha were determined against the thirty-due clinical isolates of U. urealyticum. The pure flavonoid compounds luteolin, rutin, luteolin 3,7-diglucoside and apigenin-7-O-glucoside were tested against the three ATCC strains of U. urealyticum and the clinical isolates. The broth microdilution method, according to CLSI [20] , was used. The MIC was defined as the lowest concentration of compound which inhibited the color change in the broth at the time when the color of the control tube changed and the pH of the medium increased from pH 6.0 to pH 6.5 [21] . The MICs were read after an overnight incubation. All experiments were performed in triplicate. A positive control using antibiotics (azithromycin and erythromycin) and a negative control were included in each assay.

3. Results

The results of the in vitro susceptibility tests of the fluid extract and the hydro-ethanolic macerate of Crataegus oxycantha are presented in Table 1. The two extracts tested were active against U. urealyticum strains, the hydro-ethanolic macerate showing the lowest MIC range (15.6 - 62.5 μg/ml). As expected, azithromycin and erythromycin showed comparable activities against the tested strains. These results showed that flavonoids present in Crataegus oxycantha were active against clinical isolates of U. urealyticum.

Table 2 reports the MICs of the four most abundant Crataegus oxycantha flavonoids against the U. urealyticum ATCC strains. All pure organic compounds, with the exception of rutin, showed activity against the strains tested, apigenin-7-O-glucoside being the most active compound (MICs in the range of 3.9 and 15.6 μg/ml), followed by luteolin 3,7-diglucoside (MICs in the range of 7.8 and 15.6 μg/ml). Table 3 reports the MICs of the pure isolated compounds against the thirty-due clinical strains of U. urealyticum. All compounds showed greater activity against clinical isolates compared to ATCC strains.

4. Discussion

The results of the present study demonstrated that flavonoids present in Crataegus

Table 1. MICs (μg/ml) of Crataegus oxycantha extracts against U. urealyticum clinical strains (32).

Table 2. MICs (μg/ml) of pure flavonoids against U. urealyticum ATCC strains (3).

Table 3. MICs (μg/ml) of pure flavonoids against U. urealyticum clinical strains (32).

oxycantha are active against ATCC strains and clinical isolates of U. urealyticum. Therefore, those plant extracts could represent a potential source of natural antimicrobials, providing useful information for the development of novel antibiotics. Purified flavonoids from Crataegus oxycantha could also be used as natural antibacterial agents to combat infections caused by Ureaplasma strains. Together with genital tract infections and infertility, Ureaplasma genus is associated with adverse pregnancy outcomes and diseases in the newborn, as well as an increased frequency in HIV-infected patients.

Benmalek et al. [22] have quantified the flavonoids present in Crataegus oxycantha spp. monogyna leaves and berries and demonstrated an antimicrobial potential of these extracts against Pseudomonas aeruginosa and Staphylococcus aureus.

Medicinal plants known to contain a range of phenolic compounds and flavonoids could be used to treat diseases originated by multidrug resistant bacteria. The activity of the plant extract may result from the synergistic interaction of the bioactives present. In this study we have shown that both the fluid extract and the hydro-ethanolic macerate from Crataegus oxycantha, as well as the major purified compounds, were active against the tested strains. Su et al. [23] have recently demonstrated the antibacterial activities of six polyphenols, including luteolin and quercetin, against clinical isolates of methicillin-resistant S. aureus (MRSA): synergistic and additive effects were observed when the combination of the two compounds was tested, without evidence of antagonistic effect. We have previously demonstrated that flavonoids from almond skins were active against food-borne pathogens and the interactions between compounds can alter the antimicrobial effectiveness [6] . We observed a synergism between naringenin and protocatechuic acid against S. aureus and Salmonella enterica, between naringenin and epicatechin against S. enterica and S. aureus and between protocatechuic acid and epicatechin against S. aureus. In this study we have shown that the flavonoid glycosides, including luteolin 3,7-diglucoside and apigenin-7-O-glucoside were the most active isolated compounds against U. urealyticum strains. However, when combined with the aglycones in the extract, their activity was reduced.

The activity of purified flavonoids could result in different susceptibility against species with various origins and background [24] . The low MIC ranges obtained with luteolin 3,7-diglucoside and apigenin-7-O-glucoside, could be used to develop therapeutic combinations between the purified flavonoid and macrolides, tetracyclines and fluoroquinolones, for which resistance has been reported. Recent results suggested that fruit flavonoids in their aglycone forms or as 3-O-glycosides were able to modulate norfloxacin-resistance in S. aureus strains over-expressing the norA gene [25] . A range of phenolic compounds identified in olive leaves, including luteolin7-O-glucoside, rutin, apigenin 7-O-glucoside and luteolin 4-O-glucoside, showed antibacterial and antifungal action [26] . The aglycone apigenin was active against five pathogens, including Pseudomonas aeruginosa, Salmonella typhimurium, Klebsiella pneumoniae, Enterobacter aerogenes and Proteus mirabilis, the latter showing the maximum diameter of inhibition zone [27] . Luteolin and quercetin have been recently proposed in combination with ceftazidime for the treatment of infections caused by Streptococcus pyogenes: the mechanisms of action of the synergistic effect observed related to an inhibition of peptidoglycan synthesis, increased cytoplasmic membrane permeability and decreased nucleic acid when the protein content of the bacterial cells was enhanced [28] .

In the present study erythromycin was inhibitory to U. urealyticum clinical isolates, with MIC ranges between 0.48 and 1.95 μg/ml. However, in a previous investigation, the U. urealyticum isolates were inhibited by erythromycin at MICs ranging from 0.06 - ≥256 μg/ml and 16% of the tested strains were highly resistant to this antibiotic, with MIC values ≥256 μg/ml [21] . This trend demonstrated the isolates used in the present study had not developed antibiotic resistance to macrolides.

5. Conclusion

In summary the results of the present study showed that flavonoids from Crataegus oxycantha are effective against clinical isolates of U. urealyticum. However, further studies need to be performed to understand the precise mechanisms responsible for these interactions.

Cite this paper

Bisignano, C., Furneri, P.M. and Mandalari, G. (2016) In Vitro Efficacy of Crataegus oxycantha L. (Hawthorn) and Its Major Components against ATCC and Clinical Strains of Ureaplasma urealyticum. Advances in Microbiology, 6, 909-916.


  1. 1. Redelinghuys, M.J., Ehlers, M.M., Dreyer, A.W., Lombaard, H.A. and Kock, M.M. (2014) Antimicrobial Susceptibility Patterns of Ureaplasma Species and Mycoplasma hominis in Pregnant Women. BMC Infectious Diseases, 14, 171.

  2. 2. Beuchat, L.R. and Golden, D.A. (1989) Antimicrobials Occurring Naturally in Foods. Food Technology, 43, 134-142.

  3. 3. Gould, G.W. (1996) Industry Perspectives on the Use of Natural Antimicrobials and Inhibitors for Food Applications. Journal of Food Protection, 59, 82-86.

  4. 4. Cushnie, T.P.T. and Lamb, A.J. (2011) Recent Advances in Understanding the Antibacterial Properties of Flavonoids. International Journal of Antimicrobial Agents, 38, 99-107.

  5. 5. Zuo, G.-Y., Zhang, X.-J., Yang, C.-X., Han, J., Wang, G.-C. and Bian, Z.-Q. (2012) Evaluation of Traditional Chinese Medicinal Plants for Anti-MRSA Activity with Reference to the Treatment Record of Infectious Diseases. Molecules, 17, 2955-2967.

  6. 6. Mandalari, G., Bisignano, C., D’Arrigo, M., Ginestra, G., Arena, A., Tomaino, A. and Wickham, M.S.J. (2010) Antimicrobial Potential of Polyphenols Extracted from Almond Skins. Letters in Applied Microbiology, 51, 83-89.

  7. 7. Bisignano, C., Filocamo, A., La Camera, E., Zummo, S., Fera, M.T. and Mandalari, G. (2013) Antibacterial Activities of Almond Skins on cagA-Positive and -Negative Clinical Isolates of Helicobacter pylori. BMC Microbiology, 13, 103.

  8. 8. Bisignano, C., Filocamo, A., Faulks, R.M. and Mandalari, G. (2013) In Vitro Antimicrobial Activity of Pistachio (Pistacia vera L.) Polyphenols. FEMS Microbiology Letters, 341, 62-67.

  9. 9. Mandalari, G., Bennett, R.N., Bisignano, G., Trombetta, D., Saija, A., Faulds, C.B., Gasson, M. and Narbad, A. (2007) Antimicrobial Activity of Flavonoids Extracted from Bergamot (Citrus bergamia Risso) Peel, a Byproduct of the Essential Oil Industry. Journal of Applied Microbiology, 103, 2056-2064.

  10. 10. Filocamo, A., Bisignano, C., Mandalari, G. and Navarra, M. (2015) In Vitro Antimicrobial Activity and Effect on Biofilm Production of a White Grape Juice (Vitis vinifera) Extract. Evidence-Based Complementary and Alternative Medicine, 2015, 856243.

  11. 11. Bisignano, C., Filocamo, A., Ginestra, G., Giofre’, S.V., Navarra, M., Romeo, R. and Mandalari, G. (2004) 3,4-DHPEA-EA from Olea europaea L. Is Effective against Standard and Clinical Isolates of Staphylococcus sp. Annals of Clinical Microbiology and Antimicrobials, 13, 24.

  12. 12. Furneri, P.M., Mondello, L., Mandalari, G., Paolino, D., Dugo, P., Garrozzo, A. and Bisignano, G. (2012) In Vitro Antimycoplasmal Activity of Citrus bergamia Essential Oil and Its Major Components. European Journal of Medicinal Chemistry, 52, 66-69.

  13. 13. Filocamo, A., Bisignano, C., Ferlazzo, N., Cirmi, S., Mandalari, G. and Navarra, M. (2015) In Vitro Effect of Bergamot (Citrus bergamia) Juice against cagA-Positive and -Negative Clinical Isolates of Helicobacter pylori. BMC Complementary and Alternative Medicine, 15, 256.

  14. 14. Mills, S. and Bone, K. (2000) Principles and Practice of Phytotherapy: Modern Herbal Medicine. Churchill Livingdtone, Edinburg, 439-447.

  15. 15. Jayalakshmi, R., Thirupurasundari, C.J. and Devaraj, S.N. (2006) Pretreatment with Alchoholic Extract of Crataegus oxycantha (AEC) Activates Mitochondrial Infacrtion during Isoproterenol-Induced Myocardial Infarction in Rats. Molecular Cellular Biochemistry, 292, 59-67.

  16. 16. Ficarra, P., Ficarra, R., De Pasquale, A., Monforte, M.T. and Calabro’ M.L. (1990) High-Performance Liquid Chromatography of Flavonoids in Crataegus oxycantha L. Il Farmaco, 45, 247-255.


  18. 18. Caschetto, S., Bisignano, G., Maugeri, G., Strano, V. and Albanese, A. (1983) Incidenza e ruole dei micoplasmi nelle vaginiti. Attual Ost Gin., 29, 111.

  19. 19. Shepard, M.C. (1983) Culture Media for Ureaplasmas. In: Razin, S. and Tully, J.G., Eds., Methods in Mycoplasmology, Vol. 1, Academic Press, Inc., New York, 137-146.

  20. 20. Clinical and Laboratory Standards Institute (CLSI) (2012) Clinical and Laboratory Standards Institute Performance Standards for Antimicrobial Susceptibility Testing; Twentieth Informational Supplement. CLSI, Wayne.

  21. 21. Furneri, P.M., Bisignano, G., Cerniglia, G., Nicoletti, G., Cesana, M. and Tempera, G. (1994) In Vitro Antimycoplasmal Activities of Rufloxacin and Its Metabolite MF922. Antimicrobial Agents and Chemotherapy, 38, 2651-2654.

  22. 22. Benmalek, Y., AitYahia, O., Belkebir, A. and Fardeau, M.-L. (2013) Anti-Microbial and Anti-Oxidant Activities of Illicium verum, Crataegus oxyacantha spp monogyna and Allium cepa Red and Qhite Varieties. Bioengineered, 4, 244-248.

  23. 23. Su, Y., Ma, L., Wen, Y., Wang, H. and Zhang S. (2014) Studies of the in Vitro Antibacterial Activities of Several Polyphenols against Clinical Isolates of Methicillin-Resistant Staphylococcus aureus. Molecules, 19, 12630-12639.

  24. 24. Taguri, T., Tanaka, T. and Kouno, I. (2004) Antimicrobial Activity of 10 Different Plant polYphenols against Bacteria Causing Food-Borne Disease. Biological and Pharmacological Bulletin, 27, 1965-1969.

  25. 25. Diniz-Silva, H., Magnani, M., de Siqueira, S., Leite de Souza, E. and de Siqueira-Junior, J.P. (2016) Fruit Flavonoids as Modulators of Norfloxacin Resistance in Staphylococcus aureus That Overexpressed NorA. LWT—Food Science and Technology, 1-12.

  26. 26. Pereira, A.P., Ferreira, I.C.F.R., Marcelino, F., Valentao, P. Andrade, P.B., Seabra, R., Estevinho, L., Bento, A. and Pereira, J.A. (2007) Phenolic Compounds and Antimicrobial Activity of Olive (Olea europaea L. Cv. Cobrancosa) Leaves. Molecules, 12, 1153-1162.

  27. 27. Nayaka, H.B., Londonkar, R.L., Umesh, M.K. and Tukappa, A. (2014) Antibacterial Attributes of Apigenin, Isolated from Portulaca oleracea L. International Journal of Bacteriology, 2014, Article ID: 175851.

  28. 28. Siriwong, S., Thumanu, K., Hengpratom, T. and Eumkeb, G. (2015) Synergy and Mode of Action of Ceftazidime plus Quercetin or Luteolin on Streptococcus pyogenes. Evidence-Based Complementary and Alternative Medicine, 2015, Article ID: 759459.